A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder
NCT00170755
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
718
Enrollment
INDUSTRY
Sponsor class
Conditions
Overactive Bladder Syndrome
Interventions
DRUG:
Darifenacin
Sponsor
Novartis